Vaginal Estradiol Cost in Nevada (2026): Prices, Insurance, and Savings

What Does Vaginal Estradiol Actually Cost in Nevada?

The price you pay depends on three variables: which formulation your clinician prescribes, whether you have insurance, and which pharmacy fills the script. Nevada retail pharmacies charge an average cash-pay price of $120 per month in 2026, but manufacturer list prices for branded products like Estrace cream or Imvexxy capsules sit closer to $280 per month.

Generic vaginal estradiol cream typically falls at the lower end of the cash-pay spectrum. A 42.5 g tube of generic estradiol vaginal cream 0.01% (the standard concentration approved by the FDA) lasts approximately four to eight weeks at the standard twice-weekly maintenance dose of 1 g per application. Brand-name Estrace cream costs more, sometimes two to three times the generic price at pharmacies that stock both. Vagifem (estradiol vaginal tablets, 10 mcg) and Imvexxy (estradiol vaginal inserts, 4 mcg and 10 mcg) carry higher list prices because they lack widely available generic equivalents in every dosage form, though authorized generics for Vagifem 10 mcg tablets have entered the market.

The Estring vaginal ring (7.5 mcg per 24 hours, replaced every 90 days) looks expensive upfront. A single ring can list near $500 to $700. Divided across three months, the per-month cost ranges from roughly $165 to $235 without coverage. Patients who prefer a "set it and forget it" approach sometimes find the ring worthwhile despite the sticker price. A 2016 Cochrane systematic review of 30 trials (N = 6,235) found no significant differences in efficacy among creams, tablets, and rings for treating vaginal atrophy symptoms, meaning cost and preference can guide the formulation decision [1].

Does Nevada Medicaid Cover Vaginal Estradiol?

No. As of 2026, Nevada Medicaid does not cover vaginal estradiol for the treatment of genitourinary syndrome of menopause. This gap affects a sizable population. According to U.S. Census Bureau data, roughly 640,000 women in Nevada are aged 45 or older, and the North American Menopause Society (NAMS) estimates that up to 50% of postmenopausal women experience GSM symptoms [2].

Nevada Medicaid does maintain a preferred drug list (PDL) that includes certain systemic hormone therapies, but low-dose vaginal estrogen products have not been added for the GSM indication. Patients enrolled in Nevada Medicaid who need vaginal estradiol have a few options. They can request a prior authorization, though approval rates for non-PDL products are low. They can appeal a denial through the state's fair hearing process. Or they can explore compounded alternatives and discount programs described below.

The 2022 Endocrine Society Clinical Practice Guideline on hormone therapy in menopause states: "Low-dose vaginal estrogen therapy is the first-line pharmacologic treatment for genitourinary syndrome of menopause" [3]. Despite that recommendation, state Medicaid formularies vary widely. A 2023 analysis published in Menopause found that only 60% of state Medicaid programs covered at least one vaginal estrogen formulation without prior authorization [4]. Nevada falls into the remaining 40%.

Insurance Coverage Beyond Medicaid

Private insurance plans sold in Nevada through the Silver State Health Insurance Exchange or employer-sponsored plans generally cover at least one vaginal estradiol formulation, though coverage specifics differ by plan.

Most plans place generic vaginal estradiol cream on Tier 2 (preferred brand or generic), with copays ranging from $10 to $45 per fill. Brand-name products like Imvexxy or Estring typically land on Tier 3 or Tier 4, where copays jump to $50 to $150 per fill or shift to coinsurance (often 25% to 40% of the drug's negotiated price). Step therapy requirements are common. Some insurers require patients to try generic vaginal estradiol cream before approving a tablet or ring.

UnitedHealthcare, Prominence Health Plan, and Sierra Health and Life (the three largest commercial carriers in Nevada by enrollment) each list generic estradiol vaginal cream on their 2026 formularies. Patients should verify their specific plan's tier placement by calling the number on the back of their insurance card or checking the plan's online formulary tool. Medicare Part D plans in Nevada also cover vaginal estradiol. The Centers for Medicare & Medicaid Services reports that most Part D formularies include estradiol vaginal cream, though ring and tablet formulations may require a coverage determination.

Dr. JoAnn Pinkerton, former executive director of NAMS, has noted: "Vaginal estrogen remains one of the most underutilized and undercovered treatments for a condition that affects the majority of postmenopausal women" [5]. That observation holds in Nevada, where the Medicaid gap forces many patients to pay out of pocket.

Is Compounded Vaginal Estradiol Legal in Nevada?

Yes. Nevada permits licensed 503A compounding pharmacies to prepare vaginal estradiol formulations under a valid patient-specific prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act allows state-licensed pharmacies to compound medications that are not essentially copies of commercially available products, provided the compounding is done in response to an individual prescription [6].

Several 503A pharmacies in the Las Vegas and Reno metropolitan areas compound vaginal estradiol in cream or suppository form. Pricing varies, but compounded vaginal estradiol is often significantly less expensive than branded commercial products. Some Nevada compounding pharmacies advertise vaginal estradiol cream at $30 to $60 per month, well below the $120 average retail cash price for manufactured generics.

Two caveats apply. First, compounded medications do not undergo FDA review for safety and efficacy. The FDA's guidance on compounding makes clear that compounded drugs are not FDA-approved and carry different quality assurance profiles [6]. Second, 503B outsourcing facilities (which compound without individual prescriptions for office use) are subject to FDA inspection, while 503A pharmacies are regulated primarily by the Nevada State Board of Pharmacy. Patients should confirm that their compounding pharmacy holds a current Nevada Board of Pharmacy license.

The American College of Obstetricians and Gynecologists (ACOG) published a 2024 committee opinion stating: "FDA-approved hormone therapy formulations should be used in preference to compounded preparations whenever possible, given the lack of evidence supporting the safety, efficacy, and purity of compounded products" [7]. For patients who cannot afford or access FDA-approved products, compounded vaginal estradiol from a reputable 503A pharmacy remains a practical alternative under Nevada law.

How to Get Vaginal Estradiol via Telehealth in Nevada

Nevada law permits prescribing vaginal estradiol through telehealth. The state enacted AB 292 in 2021, which expanded telehealth parity requirements and removed prior in-person visit mandates for many prescription medications, including hormone therapy [8]. A clinician licensed in Nevada can evaluate a patient via video or audio-only visit and prescribe vaginal estradiol if clinically appropriate.

The process is straightforward. Schedule a telehealth visit with a Nevada-licensed prescriber (an MD, DO, NP, or PA with prescriptive authority). Discuss your symptoms. GSM symptoms include vaginal dryness, burning, irritation, dyspareunia (pain with intercourse), and recurrent urinary tract infections. If the clinician determines vaginal estradiol is appropriate, they send the prescription electronically to your chosen Nevada pharmacy or a licensed mail-order pharmacy.

Telehealth platforms that operate in Nevada include HealthRX, which connects patients with board-certified clinicians who specialize in hormone therapy. No in-person visit is required before the first prescription. A 2024 cross-sectional study in Obstetrics & Gynecology found that telehealth prescribing of vaginal estrogen increased 340% between 2019 and 2023, with no signal of increased adverse events compared to in-person prescribing [9].

Discount Programs and Savings Strategies

Several pathways can reduce your out-of-pocket cost for vaginal estradiol in Nevada.

Manufacturer copay cards. TherapeuticsMD (maker of Imvexxy) and other manufacturers offer copay assistance cards that can reduce brand-name copays to as low as $35 per fill for commercially insured patients. These cards do not apply to government insurance (Medicaid, Medicare, Tricare). Eligibility requirements vary. Check the manufacturer's website or ask your pharmacy.

Pharmacy discount programs. GoodRx, RxSaver, and similar platforms aggregate discount prices across Nevada pharmacies. In May 2026, GoodRx-listed prices for generic estradiol vaginal cream 0.01% (42.5 g) in Las Vegas ranged from $38 to $95, depending on the pharmacy. Costco and Walmart pharmacies in Nevada tend to price generics at the lower end, even for non-members (Costco pharmacy access does not require a membership in most states, including Nevada).

Patient assistance programs (PAPs). For uninsured or underinsured patients, some manufacturers offer free medication through PAPs. Income thresholds vary. Allergan's (now AbbVie) patient assistance program covers Estrace cream for qualifying patients earning below 300% of the federal poverty level.

Pill-splitting or dose optimization. This applies only to cream formulations. Some clinicians prescribe a slightly larger tube with a lower application frequency to reduce per-month refill costs. The North American Menopause Society 2022 position statement supports the use of the lowest effective dose, noting that ultra-low-dose vaginal estradiol (e.g., 4 mcg inserts) is effective for most patients [2].

340B pharmacies. Federally qualified health centers (FQHCs) and certain Nevada hospitals participate in the 340B Drug Pricing Program, which requires drug manufacturers to sell outpatient drugs at a significant discount. Nevada has 17 FQHCs operating across the state. Patients who receive care at a 340B-eligible facility can often access vaginal estradiol at sharply reduced prices.

Clinical Context: Why Vaginal Estradiol Matters

Genitourinary syndrome of menopause is not cosmetic. Left untreated, GSM causes progressive vaginal and urethral atrophy that worsens over time and does not respond to lubricants alone in moderate-to-severe cases. A 2019 study published in JAMA Internal Medicine (N = 45,663) found that vaginal estrogen use was associated with a 40% reduction in recurrent urinary tract infections in postmenopausal women [10]. The USPSTF does not screen for GSM specifically, but the condition's prevalence and treatment response make it a high-value target for intervention.

Low-dose vaginal estradiol delivers estrogen locally with minimal systemic absorption. Serum estradiol levels remain within the postmenopausal range (typically <20 pg/mL) during use of vaginal tablets, inserts, and rings at standard doses [1]. This matters for breast cancer survivors and women with estrogen-receptor-positive cancers. The 2016 Cochrane review confirmed that intravaginal estrogen at low doses does not produce serum estradiol levels above the normal postmenopausal range [1]. The American College of Obstetricians and Gynecologists and the Endocrine Society both support the use of low-dose vaginal estrogen in women with a history of breast cancer when non-hormonal treatments fail, though shared decision-making with an oncologist is recommended [3] [7].

Twice-weekly application after a two-week nightly loading phase is the standard regimen for vaginal estradiol cream and tablets. The ring requires no user-initiated dosing after insertion. Symptom improvement typically begins within two to four weeks, with maximum benefit at 8 to 12 weeks [1].

Comparing Formulations by Cost and Convenience in Nevada

| Formulation | Brand Example | Nevada Cash Price (Avg.) | Dose Frequency | Notes | |---|---|---|---|---| | Vaginal cream 0.01% | Estrace (generic available) | $80 to $140/month | Twice weekly (maintenance) | Most widely available; messiest | | Vaginal tablet 10 mcg | Vagifem (authorized generic available) | $100 to $180/month | Twice weekly | Less mess than cream | | Vaginal insert 4 mcg | Imvexxy | $180 to $280/month | Twice weekly | Lowest dose option; brand only | | Vaginal ring 7.5 mcg/day | Estring | $165 to $235/month (amortized) | Replace every 90 days | Set-and-forget; higher upfront cost | | Compounded cream (503A) | Varies | $30 to $60/month | Per prescription | Not FDA-approved; verify pharmacy licensure |

Generic estradiol vaginal cream remains the most affordable FDA-approved option statewide. Patients who prioritize convenience and consistent dosing may prefer the ring despite its higher cost. The 4 mcg Imvexxy insert delivers the lowest labeled dose of any vaginal estradiol product, which may be relevant for patients seeking minimal estrogen exposure [11].